廣州發展(600098.SH):子公司與BP新加坡公司簽署液化天然氣購銷協議
格隆匯7月6日丨廣州發展(600098.SH)公吿,2021年7月6日,公司董事會審議通過《關於公司下屬全資子公司廣州發展天然氣貿易有限公司簽署液化天然氣購銷協議的議案》。
公司全體董事一致同意公司下屬全資子公司廣州發展天然氣貿易有限公司(簡稱“天然氣貿易公司”)與BP SINGAPORE PTE. LTD. (新加坡私人有限公司(簡稱“BP新加坡公司”))簽署液化天然氣購銷協議。天然氣貿易公司將自2022年至2034年向BP新加坡公司採購天然氣,採購氣量約65萬噸/年。
合同的簽訂有利於公司落實穩定的上游資源供應量,同時滿足下游用户天然氣用氣需求、保障天然氣的穩定供應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.